Loading patent…
AssigneesBristol-Myers Squibb Company, Pfizer Inc.
InventorsJing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. LeBlanc, Haichun Huang
Estimating the term…
The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
An isolated binding molecule that competes for binding to human OX40R with an antibody that comprises:
An isolated binding molecule that binds to human OX40R, comprising:
An isolated binding molecule that binds to human OX40R, comprising:
An isolated binding molecule that binds to human OX40R, comprising:
An isolated binding molecule that binds to human OX40R, comprising:
An isolated binding molecule that binds to human OX40R, comprising:
An isolated binding molecule that binds to human OX40R, comprising:
An isolated binding molecule that binds to human OX40R, comprising:
An isolated binding molecule that binds to human OX40R, comprising:
An isolated human monoclonal antibody that binds to human OX40R, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
An isolated human monoclonal antibody that binds to human OX40R, which comprises a light chain comprising the amino acid sequence of SEQ ID NO:
An isolated human monoclonal antibody that binds to human OX40R, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
An isolated human monoclonal antibody that binds to human OX40R, which comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.